Herpes Simplex Virus Oncolytic Therapy Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic viral therapies for cancer treatment face challenges in efficiently targeting tumour cells due to low specificity of systemically administered herpes simplex virus (HSV) variants, limiting their therapeutic effectiveness.
Innovation Solution
Redesigning the tropism of HSV by embedding single-chain antibodies (scFv) into the viral envelope via fusion with glycoprotein D and H/L, specifically linking scFv to the N-terminus of truncated glycoprotein D and H/L heterodimers to redirect viral infectivity towards tumour markers, thereby enhancing targeting specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemically administered HSV variants are used for oncolytic therapy, then broad bioavailability is achieved, but targeting specificity to tumour cells deteriorates
Solution Approach 1:
The patent applies local quality by modifying only specific glycoproteins (gD and gH/gL) on the viral envelope to incorporate tumour-targeting ligands, while maintaining the overall HSV structure and its ability to systemically circulate. This localized modification enables the virus to retain broad bioavailability while acquiring specific tumour cell recognition capabilities through the added targeting moieties.
Solution Approach 2:
The invention creates composite viral particles by combining HSV structural components with exogenously introduced tumour-targeting ligands (such as single-chain antibodies or peptide ligands). This composite structure integrates the systemic delivery capability of HSV with the specific binding properties of the targeting ligands, resolving the contradiction between broad distribution and precise targeting.
2Measurement precision
If viral tropism is redirected by incorporating ligands into the viral envelope, then tumour cell targeting is improved, but device complexity increases
Solution Approach 1:
The patent employs glycoproteins gD and gH/gL that serve multiple functions: they are essential for natural HSV entry into cells, and simultaneously serve as platforms for attaching tumour-targeting ligands. This multi-functionality allows the same viral components to mediate both general cellular entry and specific tumour targeting, reducing the need for additional complex structural elements.
Solution Approach 2:
The invention modifies the chemical properties of viral envelope glycoproteins by conjugating ligands to them, changing the binding parameters of the virus without fundamentally altering its structure. This parameter change approach (adding binding specificity through ligand conjugation) is simpler than redesigning the entire viral architecture, thus improving targeting while limiting complexity increase.
3Ease of operation
If wide bioavailability of HSV-1 entry mediators is present, then systemic delivery is facilitated, but ability to efficiently target cells of interest deteriorates
Solution Approach 1:
The patent introduces tumour-targeting ligands as intermediary molecules that bridge the HSV virus and tumour cell receptors. These ligands (such as single-chain antibodies or peptide ligands) act as mediators that guide the virus to specific tumour cells while the virus itself maintains its ability to systemically distribute throughout the body, thus resolving the contradiction between easy systemic delivery and efficient cell targeting.
Data Source
AI summary
Herpes Simplex Viruses are disclosed having single-chain antibodies (scFv) embedded in the viral envelope via fusion with glycoprotein D and with glycoprotein H and L.